Aetas Pharma Co., Ltd.   Report issue

For profit Phase 2
Founded: Tokyo Japan (2000)
Status: No NME R&D (2000)

Organization Overview

First Clinical Trial
2017
NCT03055403
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Aetas Pharma Co., Ltd.

Active Ingredients

Drugs in Phase 2 Trials (1)

m201-a (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atrial Fibrillation (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 1